Top NYC, NY Pharma Companies With Best Stability & Growth (170)
Formation Bio is a tech-driven pharma company differentiated by radically more efficient drug development. Formation Bio has built a technology platform that optimizes all aspects of drug development, enabling more efficient trial design, faster trial completion, and higher quality trial data capture. Formation Bio acquires clinical-stage drugs from pharma and biotech and develops them faster and more efficiently, unlocking greater...
Formation Bio's Top Stability & Growth Strengths
Investor Backing & Capital Strength: Capital raised is described as substantial, with a $372M Series D in June 2024 led by a16z and participation from Sanofi, explicitly earmarked to grow the pipeline and AI platform. References to $600M+ in total funding and ongoing hiring point to a reinforced capital base supporting expansion.
Strategic Partnerships: Collaborations with Sanofi and OpenAI are presented as first-in-class efforts to apply AI across drug development, signaling external validation and increased resourcing. A 2025 Sanofi licensing deal worth up to €545M further indicates the capability to progress and transact assets with blue‑chip partners.
Product Line Growth: Pipeline activity is shown to be broadening via in‑licensing (e.g., a CNS‑penetrant TYK2 inhibitor in Dec 2025) and movement into the clinic, including first‑in‑human dosing on June 9, 2026. Together, these moves suggest more programs are entering and advancing through clinical stages.
Schrödinger is a leading provider of advanced molecular simulations and enterprise software solutions and services for pharmaceutical, biotechnology, and materials science research. The predictive power of Schrödinger's software allows scientists to accelerate their research and development, reduce research costs, and make novel discoveries.
Schrödinger, Inc.'s Top Stability & Growth Strengths
Strong Revenue Growth: Total revenue grew 23% year over year to $255.9M in 2025, with software up 10.6% and drug discovery more than doubling to $56.4M. Guidance for 2026 points to 10–15% software ACV growth, and Q1 2026 ACV rose 12% year over year.
Strategic Partnerships: Royalty‑eligible collaborative programs increased to 16 by year‑end 2025, with multiple partner milestones (e.g., Takeda’s TYK2 from Nimbus, Structure Therapeutics updates) and integrations like Lilly’s TuneLab in LiveDesign signaling ecosystem momentum. These relationships can generate milestones and potential royalties that support future growth.
Investor Backing & Capital Strength: Cash and marketable securities were about $402M at year‑end 2025 (approximately $406M at Q1 2026), and operating expenses are guided below 2025 levels for 2026. This liquidity and cost discipline provide runway to advance the hosted transition and the discovery portfolio.
At PatientPoint, we're transforming every doctor-patient interaction with cutting-edge, technology-driven solutions designed to improve health outcomes and quality of life. By delivering impactful, digital, in-office patient education at no cost to physicians across the country, we empower healthcare professionals to connect more meaningfully with their patients. Through partnerships with trusted healthcare brands like Pfizer, P&G, Sanofi, Merck, NatureMade, and Bristol...
PatientPoint's Top Stability & Growth Strengths
Strong Market Position & Advantage: PatientPoint is described as the nation’s largest digital point‑of‑care network, citing roughly 30,000–35,000 physician offices and about 145,000 screens, signaling outsized scale. Expanded Media Rating Council accreditation in April 2026 across its full screen network can further strengthen advertiser confidence and budgets.
Product Line Growth: In 2026 the company launched programmatic buying via PatientPoint Health Audiences and introduced a Consumer Health Network for CPG/OTC brands, broadening monetization avenues. These moves are positioned to expand the addressable revenue beyond traditional pharma channels.
Investor Backing & Capital Strength: Advent International signed a definitive agreement to acquire PatientPoint in August 2025, framed as a catalyst to accelerate network expansion and product innovation. Such backing is presented as a strong vote of confidence in both the company and the point‑of‑care media category.
At Inato, we’re on a mission to accelerate the pace of medical innovation by bringing clinical research to each and every patient, regardless of who they are and where they live. Our platform, made to connect community-based research centers to trials across the globe, aims to create greater visibility, access, and engagement across a more diverse population of doctors and...
Inato's Top Stability & Growth Strengths
Innovation-Driven Growth: AI site selection and AI patient pre-screening launched in 2025–2026 are described as streamlining screening and improving enrollment efficiency. These releases signal a deepening product footprint aligned to faster activation and more representative enrollment.
Strategic Partnerships: A 2025 data partnership with RealTime eClinical Solutions and highlighted work with major pharma logos are presented as ecosystem validation and traction. These collaborations integrate site performance data and extend marketplace reach.
Market Expansion: The network is portrayed as growing from about 5,500 to 6,000+ research sites across 50+ countries into 2026. Sponsor materials and industry posts indicate steady expansion of marketplace breadth.
Our purpose ensures that patients remain at the center of all we do. We live our purpose by sourcing the best science in the world; partnering with others in the healthcare system to improve access to our medicines; using digital technologies to enhance our drug discovery and development, as well as patient outcomes; and leading the conversation to advocate for...
Pfizer's Top Stability & Growth Strengths
Product Line Growth: Launched and acquired products are scaling, with oncology assets from the Seagen deal and brands such as Padcev, oncology biosimilars, Nurtec, Lorbrena, Abrysvo, Eliquis, and the Vyndaqel family cited as key contributors. Early‑2026 updates describe a meaningful uptick from these newer and in‑line medicines.
Innovation-Driven Growth: Management highlights a robust late‑stage pipeline with numerous pivotal study starts planned in 2026 and catalysts across oncology, vaccines, and metabolic disease. Programs such as an ADC (sigvotatug vedotin) and a GLP‑1 RA (berobenatide) are positioned to convert into future approvals and launches.
Diversified Revenue Streams: Growth beneath the surface is coming from multiple non‑COVID franchises rather than a single product, spanning oncology (including Seagen’s ADCs), vaccines, neurology, and cardiovascular. This breadth is helping to offset normalization in COVID‑related sales.
Flatiron Health is a healthtech company dedicated to helping cancer centers thrive and deliver better care for patients today and tomorrow. Through clinical and data science, we translate patient experiences into real-world evidence to improve treatment, inform policy, and advance research. Cancer is smart. Together, we can be smarter. Flatiron Health is an independent affiliate of the Roche Group.
Flatiron Health's Top Stability & Growth Strengths
Product Line Growth: Multiple 2026 launches and updates, including Flatiron Telescope, AI‑extracted real‑world progression, a new AI data‑quality framework, and harmonized multinational datasets, signal an expanding offering. A strong 2026 scientific presence (e.g., ASCO/ISPOR) showcases next‑generation capabilities aligned to growing use cases.
Market Expansion: International build‑out is evident in first AI‑powered prostate cancer datasets for the UK and Germany and new collaborations across the UK and Europe. Company materials also highlight a markedly larger multinational network spanning the UK, Germany, and Japan.
Strategic Partnerships: Collaborations with Unicancer for regulatory‑grade evidence and point‑of‑care integrations with Abbott and Quest indicate deepening enterprise engagement. Participation in ecosystem programs and multi‑year collaborations suggests a partner‑led growth approach.
GoodRx is America’s healthcare marketplace. Each month, millions of people visit goodrx.com to find reliable health information and discounts for their healthcare — and we’ve helped people save $35 billion since 2011. We provide prescription discounts that are accepted at more than 70,000 pharmacies in the U.S., as well as telehealth services including doctor visits and lab tests. Our goal is...
GoodRx's Top Stability & Growth Strengths
Product Line Growth: Pharma Direct expanded rapidly, rising 41% in 2025 and 82% year over year to $52.2M in Q1 2026, while subscriptions grew 16% year over year in Q1 2026. New offerings such as Employer Direct and GoodRx Companion indicate continued build‑out of recurring and manufacturer‑aligned products.
Strategic Partnerships: Manufacturer‑sponsored pricing programs and expanded partnerships underpinned Pharma Direct’s surge, including GLP‑1 launches and broader retail coverage. The company also reported tripling its retail e‑commerce footprint and an 83% quarter‑over‑quarter jump in Rx Marketplace order volume tied to new partnerships.
Strong Market Position & Advantage: The platform is widely regarded as a leader in U.S. prescription savings, with acceptance at 70,000+ pharmacies and usage by nearly 30 million consumers and over one million healthcare professionals annually. This scale and reach reinforce its competitive position even as the business mix shifts.
.png)
Ro is a direct-to-patient healthcare company with a mission of helping patients achieve their health goals by delivering the easiest, most effective care possible. Ro is the only company to offer nationwide telehealth, labs, and pharmacy services. This is enabled by Ro's vertically integrated platform that helps patients achieve their goals through a convenient, end-to-end healthcare experience spanning from diagnosis,...
Ro (Ro.co)'s Top Stability & Growth Strengths
Strong Revenue Growth: Independent analysis indicates revenue reaccelerated in 2024 with GLP‑1 weight‑management becoming the primary engine. Signals since late 2023 point to material momentum tied to the Ro Body program.
Strategic Partnerships: Integrations with Eli Lilly (LillyDirect Zepbound vials) and Novo Nordisk (Wegovy pill launch and multi‑month subscription program) broaden branded access and price positioning on Ro’s platform. These manufacturer ties are presented as key levers for authentic supply and scaled distribution.
Market Expansion: Participation in the nationwide launch of the Wegovy pill and development of insurance‑navigation tools expand the GLP‑1 channel and lower access frictions. Movement into employer and health‑plan pathways aims to extend reach beyond purely cash‑pay dynamics.
Luceats Consulting's prime motto is to help Pharmaceutical organizations with their digital transformation initiatives. We work with the best in the industry vendors and resources to offer process automation and AI services. We offer strategy to deployment services across the leading pharmaceutical life cycle. We help organizations streamline their processes and improve productivity. We develop creative and innovative solutions using different...
PPD is now part of Thermo Fisher Scientific, the world leader in serving science. Together, Thermo Fisher and PPD are creating a unique opportunity to advance their shared pursuit to enable customers to make the world healthier by accelerating the development of new medicines. We now offer a comprehensive suite of world-class services across the clinical development spectrum – from...
Blue Earth Diagnostics is an established molecular imaging company focused on providing innovative, well-differentiated diagnostics solutions, informing patient management, and driving future therapies in cancer. Formed in 2014, Blue Earth Diagnostics’ success is driven by our management expertise and agility, supported by our demonstrated track record of rapid development and commercialization of PET radiopharmaceuticals. Blue Earth Diagnostics’ clinical focus is...
Parexel is among the world’s largest clinical research organizations (CROs), providing the full range of Phase I to IV clinical development services to help life-saving treatments reach patients faster. Leveraging the breadth of our clinical, regulatory and therapeutic expertise, our team of more than 21,000 global professionals collaborates with biopharmaceutical leaders, emerging innovators and sites to design and deliver clinical...
Parexel's Top Stability & Growth Strengths
Strong Market Position & Advantage: Feedback suggests Parexel is consistently viewed as a top-tier, full-service CRO, reinforced by repeated industry awards and strong site collaboration recognition. These signals indicate competitive strength in winning and delivering complex global programs.
Strategic Partnerships: Feedback suggests multi-year collaborations to embed advanced analytics and AI (e.g., Palantir and other AI initiatives) are intended to improve trial efficiency and differentiation. Such partnerships underscore continued investment in modernization and execution.
Market Expansion: Feedback suggests the company opened a new global headquarters in Raleigh and continues to reference a 20,000+ to 24,000+ global workforce, indicating operational scaling. Physical expansion and ongoing hiring activity support broader delivery capacity across regions.
Nuvation Bio is a global biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates. Nuvation Bio’s portfolio includes taletrectinib (ROS1), safusidenib (mIDH1), NUV-868 (BET), and NUV-1511 (DDC). Nuvation Bio was founded in 2018 by biopharma industry veteran David Hung, M.D., who previously founded Medivation, Inc., which brought to patients one of...
ALS Limited is a global leader in testing, inspection, certification, and verification services, providing comprehensive solutions across industries such as life sciences, minerals, industrial, and energy.
Garonit Pharmaceutical, a US-based multinational company owned by brothers Rohit and Nitin Garg, is making a global impact with its high-quality Active Pharmaceutical Ingredients (APIs). Headquartered in New Jersey, Garonit has expanded its reach to markets in the UK, Switzerland, Hong Kong, Brazil, and China. The company’s proactive and collaborative approach, along with a willingness to take risks, has earned...
Vantage MedTech provides comprehensive design and manufacturing services, supporting the advancement of medical technologies from concept through to product realization. Partnering with the world’s most innovative MedTech start-ups and large medical device companies, we offer feasibility support, product development and prototyping, new product development, clinical and commercial manufacturing, and after-market services to support every phase of the product life cycle....
Avet Pharmaceuticals Inc. is a rapidly growing generic pharmaceutical company engaged in the acquisition, licensing, development, marketing, sale and distribution of generic pharmaceutical products for the global prescription drug markets. Avet Pharmaceuticals provides high quality generic medicines that help patients and practitioners achieve affordable healthcare solutions. Our global supply chain network is built around centers of manufacturing and scientific excellence...
Koneksa is a leading patient-centric digital biomarker company for the pharmaceutical and biotechnology industries that develops end-to-end solutions for remotely collected clinical data. Koneksa supports agile decision-making in drug development and market strategy. By delivering integrated solutions for efficient trial designs that produce more meaningful data, Koneksa aims to revolutionize effect detection in clinical research.
At Averitas Pharma, we strive to enable people with pain to live and feel more like their true selves. With patients at the forefront of every decision we make, we want more than to envision people not limited by their pain; we work every day with passion and determination to make it a reality. We are currently helping patients by...
Lupin is a global pharmaceutical company offering Branded and Generic Formulations, Biosimilars and Active Pharmaceutical Ingredients (APIs). Founded over 50 years ago, Lupin today is a significant player in the US, India and Japan and additionally in other counties within APAC, EMEA and LATAM. It holds a global leadership position in Anti-TB and Cephalosporin segments. Today Lupin is focused on...
